Forty Seven Inc. to Host Key Opinion Leader Breakfast Symposium on FSI-174, anti-cKIT Antibody, on January 22, 2019
MENLO PARK, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a key opinion leader (KOL) breakfast symposium focused on the potential of FSI-174, its anti-cKIT antibody, on Tuesday, January 22, 2019 from 8:30 a.m. to 10:00 a.m. ET in New York, NY. Forty Seven plans to develop FSI-174 in combination with 5F9 as a non-toxic transplant conditioning regimen, as well as a treatment for targeted hematologic malignancies.
Guest speakers scheduled to present at the event include:
-- Irv Weissman, M.D.,Co-Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research -- Maria Grazia Roncarolo, M.D.,Co-Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine; George D. Smith Professor in Stem Cell and Regenerative Medicine at Stanford University; Chief, Division of Pediatric Stem Cell Transplantation and Regenerative Medicine at Stanford University; and Co-Director, Bass Center for Childhood Cancer and Blood Diseases
Additionally, Forty Seven management will provide an overview of its initial development strategy for FSI-174. The Company plans to present initial preclinical data for FSI-174 in the first half of 2019, and to complete investigational new drug application-enabling studies in 2019.
A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of the Company’s website at www.fortyseveninc.com. A replay of the webcast will be available on the Forty Seven website for 90 days following the event.
About Forty Seven Inc.:Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven’s lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin’s lymphoma and colorectal carcinoma.
For more information please visit www.fortyseveninc.com or contact firstname.lastname@example.org.
For journalist enquiries please contact Sarah Plumridge at email@example.com or phone (312) 506-5218.
For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at firstname.lastname@example.org or phone (212) 362-1200.